Astellas posts 1.5% increase in first-quarter sales, despite Vesicare revenue nearly halving

Headline results for the first quarter:

Revenue

334.1 billion yen ($3.1 billion)

+1.5%

Profit

58.5 billion yen ($539 million)

+7.3%

Note: All changes are versus the prior-year period unless otherwise stated

Other results:

  • Xtandi: 96 billion yen ($885 million), +18.2%, with sales growing in all regions due to penetration in earlier stage of prostate cancer
  • Prograf: 50.4 billion yen ($465 million), -3.4%, with growth in China of 13.2% offset by declines in the US, established and international markets
  • Betanis, Myrbetriq and Betmiga: 39.9 billion yen ($368 million), +16.1%, with sales increasing in all regions
  • Vesicare: 13.6 billion yen ($125 million), -45.6%, hit by generic competition after exclusivity for the drug ended in the US and Europe
  • US sales: 105.3 billion yen ($971 million), +2.5%
  • Japan sales: 98.5 billion yen ($908 million), +4.6%
  • Established market sales: 75.8 billion yen ($699 million), -1.4%, due to the foreign exchange rate impact
  • International sales: 34.2 billion yen ($315 million), +6.6%

Looking ahead:

Astellas reaffirmed that it expects sales in fiscal year 2019 to be 1.2 trillion yen ($11.1 billion), representing a decline of 6.3% versus the previous year, with core profit of 182 billion yen ($1.7 billion), a drop of 18.1%.

To read more Top Story articles, click here.